This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical...
New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...
CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...
CRA is a proud sponsor of the event. Josh Sherman is a panelist during the session titled “Global antitrust trends reshaping the life sciences market”...
